Hoa T. Tran

Internal Medicine
2110 Dorchester Ave Ste 101
Dorchestr Ctr, MA 02124

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 08, 2025

Increased ultra-large von Willebrand factor multimers in immune thrombocytopenia.

Increased ultra-large von Willebrand factor multimers in immune thrombocytopenia.

Journal: British journal of haematology
Published: March 22, 2025

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Journal: Blood advances
Published: October 25, 2024

MicroRNA-199a-5p may be a diagnostic biomarker of primary ITP.

MicroRNA-199a-5p may be a diagnostic biomarker of primary ITP.

Journal: British journal of haematology
Published: October 21, 2024

Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers.

Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers.

Journal: Genome biology
Published: September 18, 2023

Insulin autoimmune syndrome: not just one but two different diseases with therapeutic implications.

Insulin autoimmune syndrome: not just one but two different diseases with therapeutic implications.

Journal: Endocrinology, diabetes & metabolism case reports
Published: March 22, 2023

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: February 05, 2022

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Journal: Journal for immunotherapy of cancer
Published: April 18, 2021

Nicotinic Receptors in the Brainstem Ascending Arousal System in SIDS With Analysis of Pre-natal Exposures to Maternal Smoking and Alcohol in High-Risk Populations of the Safe Passage Study.

Nicotinic Receptors in the Brainstem Ascending Arousal System in SIDS With Analysis of Pre-natal Exposures to Maternal Smoking and Alcohol in High-Risk Populations of the Safe Passage Study.

Journal: Frontiers in neurology
Published: December 01, 2020

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.

Journal: Leukemia & lymphoma
Published: September 01, 2020

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Journal: Blood
Published: August 10, 2020

Clonal fitness inferred from time-series modelling of single-cell cancer genomes.

Clonal fitness inferred from time-series modelling of single-cell cancer genomes.

Journal: Nature
Published: May 08, 2020
Showing 1-12 of 25

Last Updated: 09/26/2026